跳到正文

Trails Edge Capital Partners, LP 13F 持仓 · 2026年Q2

Trails Edge Capital Partners 在 2026年Q2(报告期截至 2026-06-30)的 SEC 13F 申报中报告了 35 只证券,申报市值合计 6.30 亿美元。前几大持仓:LBRX(7.85%)、NRIX(6.06%)、IMCR(5.36%)。本季前 25 大持仓中:新建仓 8 只、增持 10 只、减持 6 只。

排名代码公司市值占组合股数变动
1LBRXLB PHARMACEUTICALS INC$49.4M7.85%1.5M增持
2NRIXNURIX THERAPEUTICS INC$38.2M6.06%1.6M减持
3IMCRIMMUNOCORE HLDGS PLC$33.8M5.36%1.1M增持
4TRAXFIRST TRACKS BIOTHERAPEUTICS$30.5M4.84%1.5M新建仓
5FDMT4D MOLECULAR THERAPEUTICS IN$29.6M4.70%2.2M增持
6BMRNBIOMARIN PHARMACEUTICAL INC$29.3M4.65%512,000新建仓
7DSGNDESIGN THERAPEUTICS INC$29.0M4.60%2.0M增持
8XENEXENON PHARMACEUTICALS INC$26.6M4.22%440,000减持
9MIRMMIRUM PHARMACEUTICALS INC$26.1M4.15%223,312减持
10CYTKCYTOKINETICS INC$24.5M3.90%288,089减持
11INSMINSMED INC$24.6M3.90%230,331新建仓
12SNDXSYNDAX PHARMACEUTICALS INC$24.3M3.85%1.1M增持
13NGNENEUROGENE INC$22.5M3.57%714,885减持
14KLRAKAILERA THERAPEUTICS INC$21.7M3.44%984,786新建仓
15RVMDREVOLUTION MEDICINES INC$21.7M3.44%115,750减持
16IKTINHIBIKASE THERAPEUTICS INC$18.4M2.92%9.1M增持
17INCYINCYTE CORP$17.6M2.79%155,000新建仓
18AVTXAVALO THERAPEUTICS INC$16.5M2.62%891,881新建仓
19MLTXMOONLAKE IMMUNOTHERAPEUTICS$14.6M2.32%750,000新建仓
20FTHFAETH THERAPEUTICS INC$12.9M2.05%515,335增持
21XFORX4 PHARMACEUTICALS INC$12.0M1.91%2.6M持平
22IRDOPUS GENETICS INC$11.3M1.79%2.7M增持
23SLGLSOL-GEL TECHNOLOGIES LTD$10.3M1.64%139,445增持
24AURAAURA BIOSCIENCES INC$10.2M1.63%1.4M新建仓
25IPSCCENTURY THERAPEUTICS INC$10.1M1.61%4.1M增持

来源:SEC 13F 申报文件 · 截至 2026-06-30

本期 13F-HR 中的全部持仓,以及相对上季度的变化。

13F 持仓,最新季度

来源SEC EDGAR13F-HR